Sequential TPF chemotherapy followed by concurrent chemoradiotherapy in locally advanced head and neck cancer – a retrospective analysis of toxicity and outcomes

Abstract

Background and aims

Phase III trials have shown that the addition of a taxane to cisplatin/5FU-based induction chemotherapy (TPF) improves response rates and overall survival in unresectable stage III/IV head and neck cancer. We sought to assess the tolerability, compliance and clinical outcomes of this treatment regime.

Methods

A retrospective study of patients treated within a single centre between September 2007 and November 2010. Toxicities were graded according to CTCAE version 3.0. Survival, distant metastasis and local control rates are expressed as percentages at two years using the Kaplan–Meier method.

Results

A total of 100 patients were identified (11% stage III, 86% stage IV) and 32% of patients were admitted as an emergency after TPF. The rate of neutropenic fever was 31%, this number fell to 9% when prophylactic G-CSF was used. In addition, 89% of patients underwent radical chemoradiation. Of these, 96% completed the full radiotherapy course. However, only 64% of patients received a minimum of two cycles of concurrent platinum chemotherapy. The two-year overall survival, metastasis free survival and local control rates were 62.6%, 88.5% and 73.3%, respectively.

Conclusions

TPF chemotherapy can be delivered safely in a non-trial cohort of patients. There is, however, a significant reduction in concurrent chemotherapy dose intensity. The long-term impact of this remains unclear.

Keywords

Locally advanced head and neck cancer chemoradiotherapy induction chemotherapy

Get full access to this article

View all access options for this article.

References

Seiwert

Cohen

EEW

. State-of-the-art management of locally advanced head and neck cancer. Br J Cancer 2005; 92: 1341–1348.

Pignon

le Maitre

Maillard

. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009; 92: 4–14.

Hitt R, Grau JJ, Lopez-Pousa A, et al. Final results of a randomized phase III trial comparing induction chemotherapy with cisplatin/5-FU or docetaxel/cisplatin/5-FU follow by chemoradiotherapy (CRT) versus CRT alone as first-line treatment of unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2009; 27: abstr 6009.

Hitt

Lopez-Pousa

Martinez-Trufero

. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer [Erratum appears in J Clin Oncol 2006; 24: 1015]. J Clin Oncol 2005; 23: 8636–8645.

Posner

Hershock

Blajman

. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007; 357: 1705–1715.

Lefebvre JL, Pointreau Y, Rolland F, et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): Preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 2009; 27: abstr 6010.

Lorch

Goloubeva

Haddad

. Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 2011; 12: 153–159.

Vermorken

Remenar

van Herpen

. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695–1704.

Paccagnella

Ghi

Loreggian

. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010; 21: 1515–1522.

10.

Pointreau

Garaud

Chapet

. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009; 101: 498–506.

11.

Haddad R, Tishler R, Adkins D, et al. The PARADIGM trial: A phase III study comparing sequential therapy (ST) to concurrent chemoradiotherapy (CRT) in locally advanced head and neck cancer (LAHNC): Preliminary toxicity report. J Clin Oncol 2010; 28: abstr 5563.

12.

Docetaxel based chemotherapy plus or munis induction chemotherapy to decrease events in head and neck cancer (DeCIDE) [database on the Internet]. Available at http://clinicaltrials.gov/show/NCT00117572 [cited 21st January 2012].